ORMP
Oramed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.01
+1.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 2.0M | — | 1.3M | 2.7M |
| Cost of Revenue | 61.0K | 2.0M | — | — | — |
| Gross Profit | (61.0K) | 13.0K | — | 1.3M | 2.7M |
| Operating Expenses | |||||
| R&D Expense | 4.7M | 6.4M | 6.3M | 9.0M | 27.6M |
| SG&A Expense | 9.8M | 8.7M | 6.5M | 8.1M | 15.7M |
| General & Admin Expense | 6.1M | 8.7M | 6.5M | 8.4M | 13.8M |
| Selling & Marketing Expense | — | — | — | (287.0K) | 1.9M |
| Other Expenses | (31.0K) | — | — | — | — |
| Total Operating Expenses | 14.5M | 15.1M | 12.8M | 17.1M | 43.3M |
| Cost and Expenses | 14.5M | 17.1M | 12.8M | 17.1M | 43.3M |
| Operating Income (EBIT) | (14.5M) | (15.1M) | (12.8M) | (15.8M) | (40.6M) |
| Non-Operating | |||||
| Interest Income | 1.2M | 2.4M | 5.0M | 8.0M | 3.6M |
| Interest Expense | — | — | 853.0K | 3.6M | — |
| Net Interest Income | 1.2M | 2.4M | 4.1M | 4.4M | 3.6M |
| Other Non-Op Income/Expense | 234.8M | 90.4M | (3.1M) | 20.9M | 2.9M |
| Non-Operating Income (excl Interest) | (166.2M) | (90.4M) | 2.3M | (22.9M) | — |
| EBT (Pre-Tax Income) | 220.3M | 75.3M | (15.9M) | 5.1M | (37.7M) |
| Income Tax Expense | 45.4M | 11.3M | 3.2M | — | 100.0K |
| Bottom Line | |||||
| Net Income | 174.9M | 64.0M | (19.1M) | 5.5M | (37.8M) |
| Earnings from Cont. Ops | 174.9M | 64.0M | (19.1M) | 5.1M | (37.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 174.1M | 64.0M | (19.1M) | 5.5M | (37.8M) |
| Per Share | |||||
| Basic EPS | $4.23 | $1.53 | ($0.48) | $0.14 | ($0.97) |
| Diluted EPS | $4.11 | $1.50 | ($0.48) | $0.14 | ($0.97) |
| Revenue Per Share | $0.00 | $0.05 | $0.00 | $0.03 | $0.07 |
| Shares | |||||
| Basic Shares Outstanding | 41.0M | 41.4M | 40.9M | 40.3M | 39.0M |
| Diluted Shares Outstanding | 42.5M | 42.4M | 40.9M | 40.6M | 39.0M |
| Profitability Metrics | |||||
| EBITDA | 151.8M | 75.4M | (14.9M) | 7.3M | (37.0M) |
| D&A | 91.0K | 121.0K | 193.0K | 196.0K | 3.6M |
| EBIT | 151.7M | 75.3M | (15.1M) | 7.1M | (40.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026